Glucuronidase beta is an early predictive marker for the use of antidepressant in the treatment of glioma patients

Abstract

Purpose: To screen early targets and investigate the potential molecular mechanisms involved in the use of antidepressant in the treatment of glioma. 
 Methods: The GSE89873 dataset, including expression levels of C6 cells under antidepressant treatment, non-antidepressant drug treatment, and untreated cells (control), was downloaded from database. Differentially expressed genes (DEGs) between antidepressant treatment and untreated cells, and between non-antidepressant drug treatment and untreated cells were identified and annotated. Genes that were significantly related to different drug treatment conditions were screened. 
 Results: In all, 416 differentially expressed genes (DEGs) were selected between cells of the antidepressant treatment and control groups, while 650 DEGs were selected between cells of the non-antidepressant treatment and control groups. The 402 overlapping DEGs were significantly associated with the apoptotic process, transforming growth factor beta receptor signaling pathway, and cell cycle arrest (p < 0.05). The DEGs ACOX1, ACSL1, GSTM3, and GSTP1 were significantly related to hormonal therapy (p < 0.05). Glucuronidase beta (GUSB) was significantly associated with age and targeted molecular therapy (p < 0.05). The GUSB was also significantly associated with overall survival time (p < 0.05). It is one of the unique DEGs in the antidepressant treatment group that participates in the drug metabolism-cytochrome P450 metabolic pathway. 
 Conclusion: Glucuronidase beta may be a specific biomarker for the early response of antidepressants to glioma treatment. This should, however, be further investigated to validate this finding.